Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
Kane Biotech (KNBIF) has received Internal Review Board (IRB) approval from the University of Miami Health System to begin a clinical study of their DispersinB® Acne Cleanser for treating mild to moderate Acne Vulgaris.
The study, titled 'Split-face efficacy and tolerability of DispersinB® Acne Cleanser in the treatment of mild to moderate Acne Vulgaris,' will be conducted at the University of Miami Miller School of Medicine. The trial is scheduled to commence by mid-2025 and will involve up to 24 subjects.
The research will take place at the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, which is recognized as a global leader in skin condition treatments.
Kane Biotech (KNBIF) ha ricevuto l'approvazione dal Comitato Etico (IRB) dell'Università della Florida per avviare uno studio clinico sul loro DispersinB® Acne Cleanser per il trattamento dell'Acne Vulgaris da lieve a moderata.
Lo studio, intitolato 'Efficacia e tollerabilità del DispersinB® Acne Cleanser in un trattamento split-face dell'Acne Vulgaris da lieve a moderata,' sarà condotto presso la Miller School of Medicine dell'Università di Miami. La sperimentazione è prevista per iniziare entro la metà del 2025 e coinvolgerà fino a 24 soggetti.
La ricerca si svolgerà presso il Dipartimento di Dermatologia e Chirurgia Cutanea Dr. Phillip Frost, riconosciuto come un leader globale nei trattamenti per le condizioni della pelle.
Kane Biotech (KNBIF) ha recibido la aprobación de la Junta de Revisión Interna (IRB) del Sistema de Salud de la Universidad de Miami para comenzar un estudio clínico de su DispersinB® Acne Cleanser para el tratamiento del Acné Vulgaris leve a moderado.
El estudio, titulado 'Eficacia y tolerabilidad del DispersinB® Acne Cleanser en el tratamiento del Acné Vulgaris leve a moderado,' se llevará a cabo en la Escuela de Medicina Miller de la Universidad de Miami. El ensayo está programado para comenzar a mediados de 2025 y contará con la participación de hasta 24 sujetos.
La investigación se realizará en el Departamento de Dermatología y Cirugía Cutánea Dr. Phillip Frost, que es reconocido como un líder mundial en tratamientos para condiciones de la piel.
케인 바이오텍 (KNBIF)는 마이애미 대학교 건강 시스템의 기관 윤리 위원회 (IRB)로부터 DispersinB® 여드름 클렌저의 경증에서 중등도 여드름 치료를 위한 임상 연구를 시작할 수 있는 승인을 받았습니다.
이 연구는 '경증에서 중등도 여드름 치료를 위한 DispersinB® 여드름 클렌저의 분할 얼굴 효능 및 내약성'이라는 제목으로 마이애미 대학교 밀러 의과대학에서 진행됩니다. 시험은 2025년 중반에 시작될 예정이며 최대 24명의 참가자가 포함됩니다.
연구는 피부 질환 치료의 글로벌 리더로 인정받는 Dr. Phillip Frost 피부과 및 피부 수술 학과에서 진행됩니다.
Kane Biotech (KNBIF) a reçu l'approbation du Comité d'Éthique Interne (IRB) du Système de Santé de l'Université de Miami pour commencer une étude clinique sur leur DispersinB® Acne Cleanser pour le traitement de l'Acne Vulgaris léger à modéré.
L'étude, intitulée 'Efficacité et tolérance du DispersinB® Acne Cleanser dans le traitement de l'Acne Vulgaris léger à modéré,' sera réalisée à l'École de Médecine Miller de l'Université de Miami. L'essai est prévu pour commencer d'ici la mi-2025 et impliquera jusqu'à 24 sujets.
La recherche se déroulera au Département de Dermatologie et de Chirurgie Cutanée Dr. Phillip Frost, reconnu comme un leader mondial dans les traitements des affections cutanées.
Kane Biotech (KNBIF) hat die Genehmigung der Ethikkommission (IRB) des Gesundheitssystems der Universität Miami erhalten, um eine klinische Studie zu ihrem DispersinB® Acne Cleanser zur Behandlung von leichter bis mäßiger Acne Vulgaris zu beginnen.
Die Studie mit dem Titel 'Effektivität und Verträglichkeit des DispersinB® Acne Cleanser bei der Behandlung von leichter bis mäßiger Acne Vulgaris' wird an der Miller School of Medicine der Universität Miami durchgeführt. Die Studie soll Mitte 2025 beginnen und wird bis zu 24 Probanden umfassen.
Die Forschung findet im Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery statt, das als globaler Marktführer in der Behandlung von Hauterkrankungen anerkannt ist.
- Received IRB approval to advance clinical trials for DispersinB Acne Cleanser
- Partnership with globally recognized University of Miami Health System for clinical trials
- Potential market opportunity in acne treatment sector
- Small trial size of only 24 subjects may limit statistical significance
- Trial not yet started, results pending until after mid-2025
Kane to work with the University of Miami to study DispersinB® Acne Cleanser in mild to moderate Acne Vulgaris
WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review Board (“IRB”) of the University of Miami Health System (“UHealth”) to commence a clinical study of Kane’s prototype DispersinB® Acne Cleanser for the treatment of mild to moderate cases of Acne Vulgaris.
The title of the study is “Split-face efficacy and tolerability of DispersinB® Acne Cleanser in the treatment of mild to moderate Acne Vulgaris.” The trial, which is expected to commence by mid-year, will be conducted on up to 24 subjects and will take place at the University of Miami Miller School of Medicine. The Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery at the University of Miami Health System is recognized as a global leader in caring for conditions and disorders of the skin.
“We are thrilled to receive approval from the UHealth's IRB to move forward with our trial for DispersinB® in the treatment of acne," said Marc Edwards, President & CEO of Kane Biotech. "DispersinB® represents a groundbreaking approach to tackling acne, and we believe it has the potential to significantly improve outcomes for millions of people struggling with this condition. This approval marks an important milestone as we continue advancing our mission to bring innovative, science-driven dermatological solutions to market."
About Kane Biotech
Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (66 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB®, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. Kane is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
About UHealth – University of Miami Health System
UHealth – University of Miami Health System delivers leading-edge patient care by top-ranked physicians who treat some of the most complex cases. Powered by the Miller School of Medicine’s ground-breaking research and medical education, UHealth is the region’s only academic-based health care system. With a comprehensive network of nearly 40 outpatient facilities, its flagship hospital in the heart of Miami’s Health District, and more than 2,700 providers across South Florida, UHealth is a vital component of the community that is leading the next generation of health care. UHealth is home to Bascom Palmer Eye Institute, the No. 1 ranked eye hospital in the nation by U.S. News & World Report, Sylvester Comprehensive Cancer Center, the region’s only NCI-designated cancer center, and Desai Sethi Urology Institute, dedicated to urologic research and discovery, and a neurology and neurosurgery program ranked in the top 25 in the nation. These programs along with 100 other specialties make UHealth a trusted destination for compassionate, research-based care.
For more information:
| Marc Edwards | Ray Dupuis | |||
| Chief Executive Officer | Chief Financial Officer | |||
| Kane Biotech Inc | Kane Biotech Inc | |||
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | |||
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to Kane’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Kane to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Kane with applicable securities regulatory authorities, available at www.sedarplus.ca. Kane cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
When will Kane Biotech (KNBIF) begin its DispersinB Acne Cleanser clinical trial?
How many participants will be included in Kane Biotech's (KNBIF) acne cleanser study?
What type of acne conditions will Kane Biotech's (KNBIF) DispersinB cleanser target?
Which institution approved Kane Biotech's (KNBIF) acne treatment study?
